Jeremy E Chojnacki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7277371/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PLDMS: Phosphopeptide Library Dephosphorylation Followed by Mass Spectrometry Analysis to Determine the Specificity of Phosphatases for Dephosphorylation Site Sequences. Methods in Molecular Biology, 2022, , 43-64.	0.9	1
2	Dissecting the sequence determinants for dephosphorylation by the catalytic subunits of phosphatases PP1 and PP2A. Nature Communications, 2020, 11, 3583.	12.8	38
3	Structural and mechanistic insights into the interaction of the circadian transcription factor BMAL1 with the KIX domain of the CREB-binding protein. Journal of Biological Chemistry, 2019, 294, 16604-16619.	3.4	9
4	NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer's Disease. Molecular Neurobiology, 2018, 55, 1977-1987.	4.0	153
5	Development and Characterization of a Hydroxyl-Sulfonamide Analogue, 5-Chloro- <i>N</i> -[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a Novel NLRP3 Inflammasome Inhibitor for Potential Treatment of Multiple Sclerosis. ACS Chemical Neuroscience, 2017. 8. 2194-2201.	3.5	77
6	Mechanistic Insight of Bivalent Compound 21MO as Potential Neuroprotectant for Alzheimer's Disease. Molecules, 2016, 21, 412.	3.8	9
7	Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia–reperfusion in the mouse. International Journal of Cardiology, 2016, 209, 215-220.	1.7	173
8	P4-170: Mechanistic studies of a bivalent compound containing curcumin and a membrane anchorage as a neuroprotectant in mc65 cell model. , 2015, 11, P844-P844.		0
9	P1-305: Design and evaluation of fluorescent probes to elucidate the mechanism of curcumin/melatonin hybrids for Alzheimer's disease. , 2015, 11, P473-P473.		0
10	Bivalent Compound 17MN Exerts Neuroprotection through Interaction at Multiple Sites in a Cellular Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 1021-1033.	2.6	14
11	Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse. Journal of Cardiovascular Pharmacology, 2015, 66, 1-8.	1.9	128
12	Curcumin/Melatonin Hybrid 5-(4-Hydroxy-phenyl)-3-oxo-pentanoic Acid [2-(5-Methoxy-1 <i>H</i> -indol-3-yl)-ethyl]-amide Ameliorates AD-Like Pathology in the APP/PS1 Mouse Model. ACS Chemical Neuroscience, 2015, 6, 1393-1399.	3.5	51
13	Bivalent ligands incorporating curcumin and diosgenin as multifunctional compounds against Alzheimer's disease. Bioorganic and Medicinal Chemistry, 2015, 23, 7324-7331.	3.0	29
14	A Novel Pharmacologic Inhibitor of the NLRP3 Inflammasome Limits Myocardial Injury After Ischemia–Reperfusion in the Mouse. Journal of Cardiovascular Pharmacology, 2014, 63, 316-322.	1.9	215
15	Discovery of 5-(4-Hydroxyphenyl)-3-oxo-pentanoic Acid [2-(5-Methoxy-1H-indol-3-yl)-ethyl]-amide as a Neuroprotectant for Alzheimer's Disease by Hybridization of Curcumin and Melatonin. ACS Chemical Neuroscience, 2014, 5, 690-699.	3.5	66
16	P1-400: DEVELOPMENT OF CURCUMIN/MELATONIN HYBRIDS AND THEIR POTENTIAL APPLICATION IN AD. , 2014, 10, P460-P460.		0
17	BF3·OEt2-promoted concise synthesis of difluoroboron-derivatized curcumins from aldehydes and 2,4-pentanedione. Tetrahedron Letters, 2013, 54, 2070-2073.	1.4	45
18	Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma. Organic and Biomolecular Chemistry, 2013, 11, 4757.	2.8	47

#	Article	IF	CITATIONS
19	Bivalent Ligand Containing Curcumin and Cholesterol as a Fluorescence Probe for Aβ Plaques in Alzheimer's Disease. ACS Chemical Neuroscience, 2012, 3, 141-146.	3.5	70